Scope

Products in the form of clothing or wearable items that are specially processed with catalysts or minerals so that Nitric Oxide (NO) is generated in the blood, thereby achieving the effect of blood vessel dilation and improvement of blood circulation.

Materials

Fabric materials, functional materials, composition percentages, and processing methods should be clearly identified.

Chemical Safety

When functional minerals or metals induce NO production, demonstrate that the functional materials are free of contamination by heavy metals listed in the RoHS Directive.

Performance

The product must be tested to demonstrate its efficacy in promoting changes in in vivo NO concentrations and blood flow in human subjects. The voluntary standard provides detailed information on subject selection, testing and measuring equipment, testing methods, statistical analysis, and data interpretation. Manufacturers are required to conduct the evaluation accordingly and provide evidence that the device generates a significant level of NO and improved blood circulation.

Biocompatibility

Biological safety evaluation should be conducted in accordance with ISO 10993-1 or JIS T 0993-1. Through a risk-based assessment, manufacturers should determine whether additional biological testing is required or whether existing scientific evidence is sufficient to demonstrate biocompatibility.

Other Requirements

Physical performance, durability, and stability requirements are also addressed in the voluntary standards. Manufacturers should ensure that all applicable evaluations and testing have been adequately performed and that the corresponding results are properly documented.

In Japan, Class I medical devices are generally subject to a notification-based regulatory pathway, given their extremely low risk classification. However, for “Home-use NO Generating Devices for Blood Circulation Promotion”, the claimed intended use must be adequately supported by appropriate testing and scientific evidence. Furthermore, the corresponding verification results are expected to be submitted as supporting documentation along with the notification to the PMDA.

Talk to our Japan Team now!

Understanding a new market often requires both local knowledge and regional experience. With our Japan local offices in Osaka & Yokohama and 26+ years of experience across Asia Pacific, Qualtech supports medical device companies in navigating market regulatory requirements and evaluating growth opportunities. Contact us to discuss your plans for the Japan region.

Reference

MHLW, Notice on the Voluntary Standards for Home-use Nitric Oxide Generating Devices for Blood Circulation Promotion (No. 1105-2, 5 November 2026).

分享: